NIH R01 · 2024
Multimodal analysis of the "honeymoon period" in autoimmune diabetes
The ultimate goal of this proposal is to define composite biomarkers that can be used to improve outcomes in future type 1 diabetes (T1D) clinical trials. T1D is the major cause of diabetes in youth. It is characterized by life-long insulin insufficiency due to autoimmune mediated ß cell destruction. Despite considerable efforts over the past 30+ years, effective therapies are still lacking and there is an urgent need for a cure. Natural history studies indicate that the rate of T1D progression varies greatly between individuals, both before, and after onset. Indeed, the current paucity of validated mechanistic biomarkers that can accurately predict “slow” or “fast” progression is a major…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.